From laboratory to clinic: Translation of extracellular vesicle based cancer biomarkers
•We discuss the hurdles along the extracellular vesicle-based biomarker development.•We outline the solutions for translation of EV biomarkers to clinical application.•These principles allow translation of EV based biomarkers from the bench to the bedside. The past decade has witnessed a rapid growt...
Gespeichert in:
| Veröffentlicht in: | Methods (San Diego, Calif.) Calif.), 2020-05, Vol.177, p.58-66 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 66 |
|---|---|
| container_issue | |
| container_start_page | 58 |
| container_title | Methods (San Diego, Calif.) |
| container_volume | 177 |
| creator | Yekula, Anudeep Muralidharan, Koushik Kang, Keiko M. Wang, Lan Balaj, Leonora Carter, Bob S. |
| description | •We discuss the hurdles along the extracellular vesicle-based biomarker development.•We outline the solutions for translation of EV biomarkers to clinical application.•These principles allow translation of EV based biomarkers from the bench to the bedside.
The past decade has witnessed a rapid growth in the field of extracellular vesicle (EV) based biomarkers for the diagnosis and monitoring of cancer. Several studies have reported novel EV based biomarkers, but the technical and clinical validation phase has been hampered by general challenges common to biomedical research field as well as specific challenges inherent to the nanoparticle field. This has led to more common failures than success stories in the biomarker discovery pipeline. As a result, more attention must be focused on the process of biomarker discovery, verification, and validation to allow for translation and application of novel EV based research to patient care. Herein, we briefly discuss the hurdles and potential solutions in EV biomarker discovery and verification and validation, and clinical translation. |
| doi_str_mv | 10.1016/j.ymeth.2020.02.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7198349</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1046202319303135</els_id><sourcerecordid>2388742361</sourcerecordid><originalsourceid>FETCH-LOGICAL-c492t-e570b77fb496e5d08681fe0e9dbd143b22b5328260287a6909d0d30279b564523</originalsourceid><addsrcrecordid>eNqNkU-LFDEQxRtR3HX1EwiSo5duK0l30hEUlsVVYcHLiseQP9VuxnRnTXoG59ubcdZFL-IpBfWrl1f1muY5hY4CFa823X7G9aZjwKAD1gHwB80pBTW0inJ4eKh70dY2P2melLIBAMrk-Lg54QwEFbI_bb5c5jSTaGzKZk15T9ZEXAxLcK_JdTZLiWYNaSFpIvhjzcZhjNtoMtlhCS4isaagJ84sDjOxIc0mf8NcnjaPJhMLPrt7z5rPl--uLz60V5_ef7w4v2pdr9ja4iDBSjnZXgkcPIxipBMCKm897bllzA6cjUwAG6URCpQHz4FJZQfRD4yfNW-PurdbO6N3uFSTUd_mUI3sdTJB_91Zwo3-mnZaUjXyXlWBl3cCOX3fYln1HMphS7Ng2hbN-DjKnnFB_wMdhKCyshXlR9TlVErG6d4RBX1IT2_0r_T0IT0NTNf06tSLP5e5n_kdVwXeHAGsJ90FzLq4gPX0PmR0q_Yp_PODnw1nrP4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2356617236</pqid></control><display><type>article</type><title>From laboratory to clinic: Translation of extracellular vesicle based cancer biomarkers</title><source>Elsevier ScienceDirect Journals</source><creator>Yekula, Anudeep ; Muralidharan, Koushik ; Kang, Keiko M. ; Wang, Lan ; Balaj, Leonora ; Carter, Bob S.</creator><creatorcontrib>Yekula, Anudeep ; Muralidharan, Koushik ; Kang, Keiko M. ; Wang, Lan ; Balaj, Leonora ; Carter, Bob S.</creatorcontrib><description>•We discuss the hurdles along the extracellular vesicle-based biomarker development.•We outline the solutions for translation of EV biomarkers to clinical application.•These principles allow translation of EV based biomarkers from the bench to the bedside.
The past decade has witnessed a rapid growth in the field of extracellular vesicle (EV) based biomarkers for the diagnosis and monitoring of cancer. Several studies have reported novel EV based biomarkers, but the technical and clinical validation phase has been hampered by general challenges common to biomedical research field as well as specific challenges inherent to the nanoparticle field. This has led to more common failures than success stories in the biomarker discovery pipeline. As a result, more attention must be focused on the process of biomarker discovery, verification, and validation to allow for translation and application of novel EV based research to patient care. Herein, we briefly discuss the hurdles and potential solutions in EV biomarker discovery and verification and validation, and clinical translation.</description><identifier>ISSN: 1046-2023</identifier><identifier>EISSN: 1095-9130</identifier><identifier>DOI: 10.1016/j.ymeth.2020.02.003</identifier><identifier>PMID: 32061674</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Biomarker discovery ; Biomarker validation ; Biomarkers ; biomedical research ; CLIA ; Clinical translation ; Extracellular vesicles ; monitoring ; nanoparticles ; neoplasms ; patient care</subject><ispartof>Methods (San Diego, Calif.), 2020-05, Vol.177, p.58-66</ispartof><rights>2020 Elsevier Inc.</rights><rights>Copyright © 2020 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c492t-e570b77fb496e5d08681fe0e9dbd143b22b5328260287a6909d0d30279b564523</citedby><cites>FETCH-LOGICAL-c492t-e570b77fb496e5d08681fe0e9dbd143b22b5328260287a6909d0d30279b564523</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1046202319303135$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32061674$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yekula, Anudeep</creatorcontrib><creatorcontrib>Muralidharan, Koushik</creatorcontrib><creatorcontrib>Kang, Keiko M.</creatorcontrib><creatorcontrib>Wang, Lan</creatorcontrib><creatorcontrib>Balaj, Leonora</creatorcontrib><creatorcontrib>Carter, Bob S.</creatorcontrib><title>From laboratory to clinic: Translation of extracellular vesicle based cancer biomarkers</title><title>Methods (San Diego, Calif.)</title><addtitle>Methods</addtitle><description>•We discuss the hurdles along the extracellular vesicle-based biomarker development.•We outline the solutions for translation of EV biomarkers to clinical application.•These principles allow translation of EV based biomarkers from the bench to the bedside.
The past decade has witnessed a rapid growth in the field of extracellular vesicle (EV) based biomarkers for the diagnosis and monitoring of cancer. Several studies have reported novel EV based biomarkers, but the technical and clinical validation phase has been hampered by general challenges common to biomedical research field as well as specific challenges inherent to the nanoparticle field. This has led to more common failures than success stories in the biomarker discovery pipeline. As a result, more attention must be focused on the process of biomarker discovery, verification, and validation to allow for translation and application of novel EV based research to patient care. Herein, we briefly discuss the hurdles and potential solutions in EV biomarker discovery and verification and validation, and clinical translation.</description><subject>Biomarker discovery</subject><subject>Biomarker validation</subject><subject>Biomarkers</subject><subject>biomedical research</subject><subject>CLIA</subject><subject>Clinical translation</subject><subject>Extracellular vesicles</subject><subject>monitoring</subject><subject>nanoparticles</subject><subject>neoplasms</subject><subject>patient care</subject><issn>1046-2023</issn><issn>1095-9130</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqNkU-LFDEQxRtR3HX1EwiSo5duK0l30hEUlsVVYcHLiseQP9VuxnRnTXoG59ubcdZFL-IpBfWrl1f1muY5hY4CFa823X7G9aZjwKAD1gHwB80pBTW0inJ4eKh70dY2P2melLIBAMrk-Lg54QwEFbI_bb5c5jSTaGzKZk15T9ZEXAxLcK_JdTZLiWYNaSFpIvhjzcZhjNtoMtlhCS4isaagJ84sDjOxIc0mf8NcnjaPJhMLPrt7z5rPl--uLz60V5_ef7w4v2pdr9ja4iDBSjnZXgkcPIxipBMCKm897bllzA6cjUwAG6URCpQHz4FJZQfRD4yfNW-PurdbO6N3uFSTUd_mUI3sdTJB_91Zwo3-mnZaUjXyXlWBl3cCOX3fYln1HMphS7Ng2hbN-DjKnnFB_wMdhKCyshXlR9TlVErG6d4RBX1IT2_0r_T0IT0NTNf06tSLP5e5n_kdVwXeHAGsJ90FzLq4gPX0PmR0q_Yp_PODnw1nrP4</recordid><startdate>20200501</startdate><enddate>20200501</enddate><creator>Yekula, Anudeep</creator><creator>Muralidharan, Koushik</creator><creator>Kang, Keiko M.</creator><creator>Wang, Lan</creator><creator>Balaj, Leonora</creator><creator>Carter, Bob S.</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope></search><sort><creationdate>20200501</creationdate><title>From laboratory to clinic: Translation of extracellular vesicle based cancer biomarkers</title><author>Yekula, Anudeep ; Muralidharan, Koushik ; Kang, Keiko M. ; Wang, Lan ; Balaj, Leonora ; Carter, Bob S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c492t-e570b77fb496e5d08681fe0e9dbd143b22b5328260287a6909d0d30279b564523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Biomarker discovery</topic><topic>Biomarker validation</topic><topic>Biomarkers</topic><topic>biomedical research</topic><topic>CLIA</topic><topic>Clinical translation</topic><topic>Extracellular vesicles</topic><topic>monitoring</topic><topic>nanoparticles</topic><topic>neoplasms</topic><topic>patient care</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yekula, Anudeep</creatorcontrib><creatorcontrib>Muralidharan, Koushik</creatorcontrib><creatorcontrib>Kang, Keiko M.</creatorcontrib><creatorcontrib>Wang, Lan</creatorcontrib><creatorcontrib>Balaj, Leonora</creatorcontrib><creatorcontrib>Carter, Bob S.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Methods (San Diego, Calif.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yekula, Anudeep</au><au>Muralidharan, Koushik</au><au>Kang, Keiko M.</au><au>Wang, Lan</au><au>Balaj, Leonora</au><au>Carter, Bob S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>From laboratory to clinic: Translation of extracellular vesicle based cancer biomarkers</atitle><jtitle>Methods (San Diego, Calif.)</jtitle><addtitle>Methods</addtitle><date>2020-05-01</date><risdate>2020</risdate><volume>177</volume><spage>58</spage><epage>66</epage><pages>58-66</pages><issn>1046-2023</issn><eissn>1095-9130</eissn><abstract>•We discuss the hurdles along the extracellular vesicle-based biomarker development.•We outline the solutions for translation of EV biomarkers to clinical application.•These principles allow translation of EV based biomarkers from the bench to the bedside.
The past decade has witnessed a rapid growth in the field of extracellular vesicle (EV) based biomarkers for the diagnosis and monitoring of cancer. Several studies have reported novel EV based biomarkers, but the technical and clinical validation phase has been hampered by general challenges common to biomedical research field as well as specific challenges inherent to the nanoparticle field. This has led to more common failures than success stories in the biomarker discovery pipeline. As a result, more attention must be focused on the process of biomarker discovery, verification, and validation to allow for translation and application of novel EV based research to patient care. Herein, we briefly discuss the hurdles and potential solutions in EV biomarker discovery and verification and validation, and clinical translation.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32061674</pmid><doi>10.1016/j.ymeth.2020.02.003</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1046-2023 |
| ispartof | Methods (San Diego, Calif.), 2020-05, Vol.177, p.58-66 |
| issn | 1046-2023 1095-9130 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7198349 |
| source | Elsevier ScienceDirect Journals |
| subjects | Biomarker discovery Biomarker validation Biomarkers biomedical research CLIA Clinical translation Extracellular vesicles monitoring nanoparticles neoplasms patient care |
| title | From laboratory to clinic: Translation of extracellular vesicle based cancer biomarkers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T22%3A14%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=From%20laboratory%20to%20clinic:%20Translation%20of%20extracellular%20vesicle%20based%20cancer%20biomarkers&rft.jtitle=Methods%20(San%20Diego,%20Calif.)&rft.au=Yekula,%20Anudeep&rft.date=2020-05-01&rft.volume=177&rft.spage=58&rft.epage=66&rft.pages=58-66&rft.issn=1046-2023&rft.eissn=1095-9130&rft_id=info:doi/10.1016/j.ymeth.2020.02.003&rft_dat=%3Cproquest_pubme%3E2388742361%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2356617236&rft_id=info:pmid/32061674&rft_els_id=S1046202319303135&rfr_iscdi=true |